Seeks long-term capital appreciation.
A stock fund that invests in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.
Effective 12/31/17, this Fund is closed to certain qualified pension and retirement plans. For more information, please refer to the fund's statutory prospectus.
% (as of 4/30/2020)
Average Annual Total Returns % (as of 4/30/2020)
|Hartford Healthcare HLS IA||-1.31||18.22||11.16||8.79||15.61||12.23|
|Morningstar Health Category||-1.85||13.25||10.50||6.62||14.04||---|
% (as of 3/31/2020)
Average Annual Total Returns % (as of 3/31/2020)
|Hartford Healthcare HLS IA||-13.48||1.44||6.93||5.46||13.65||11.54|
|Morningstar Health Category||-13.80||-3.66||6.71||3.28||12.64||---|
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.
Prior to 4/1/2016, the Fund's benchmark was the S&P North American Health Care Sector Index.
Excludes sales charges. If sales charges and taxes had been included, the value would have been lower.
|As of Date||4/30/2020|
|Net Assets||$207 million|
|# of Holdings||107|
|% in Equities||98|
|% in Foreign Equities||17|
|Beta (3 year)||1.08|
|R Squared (3 year)||0.88|
|Fund||S&P Composite 1500 Health Care Index|
|EPS Growth Rate||10.0%||9.2%|
|Return on Equity||3.5%||22.3%|
|Asset Weighted Market Cap (billions)||$81.8||$137.7|
|Median Market Cap (billions)||$4.7||$3.9|
|Biopharma Large Cap||23|
|Health Care Services||21|
|Biopharma Mid Cap||15|
|Biopharma Small Cap||10|
|Biopharma Large Cap||24|
|Health Care Services||18|
|Biopharma Mid Cap||18|
|Biopharma Small Cap||9|
|UnitedHealth Group, Inc.||8.05|
|Bristol-Myers Squibb Co.||4.05|
|Eli Lilly & Co.||4.05|
|Thermo Fisher Scientific, Inc.||3.62|
|Boston Scientific Corp.||2.62|
|Edwards Lifesciences Corp.||2.58|
|Total Portfolio %||39.84|
|Bristol-Myers Squibb Co.||4.19|
|Eli Lilly & Co.||4.10|
|Thermo Fisher Scientific, Inc.||3.46|
|UnitedHealth Group, Inc.||2.90|
|Vertex Pharmaceuticals, Inc.||2.69|
|Boston Scientific Corp.||2.57|
|Total Portfolio %||33.93|
|Less than $2 billion||11|
|$2 billion - $5 billion||12|
|$5 billion - $10 billion||9|
|Greater than $10 billion||68|
Log in to order forms and literature and manage your subscriptions.
0 items Selected
03/31/2020 | pdf
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
05/01/2019 | pdf
A concise summary of the Fund’s investment strategy, performance, expenses, risks, and management team.
12/02/2019 | pdf
A semi-annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.
05/01/2020 | pdf
An annual update on the Fund that includes information about the Fund’s investment manager, sub-adviser, and operations.
12/31/2019 | pdf
An annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.
05/01/2020 | pdf
A supplementary document to the Fund’s prospectus that includes additional information about the Fund and its operations.
Hartford HLS Funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). The Funds are sub-advised by Wellington Management Company LLP, which is not affiliated with HFD or HFMC.